MedTrace Logo

Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME

NCT06314217 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-31

No results posted yet for this study

Summary

This is an open-label pilot device study. The aim of the study is to evaluate the safety and performance of Everads Injector following single injection of suspension approved for ocular use into the suprachoroidal space.

The study population is patients diagnosed with diabetic macular edema (DME) that were previously treated. 10 adult subjects are expected to be enrolled based on the inclusion-exclusion criteria.

The study will involve 6 visits during a period of 6 weeks

Conditions

Interventions

DEVICE

Everads Injector

Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector

Sponsors & Collaborators

  • Everads Therapy

    lead INDUSTRY

Principal Investigators

  • Barak, MD · Rambam MC

  • Keren Mano Tamir, MD · Everads Therapy

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-18
Primary Completion
2025-03-26
Completion
2025-03-26

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314217 on ClinicalTrials.gov